Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 43 | 2020 | 1225 | 5.930 |
Why?
|
| Brain Ischemia | 32 | 2019 | 423 | 5.360 |
Why?
|
| Neuroprotective Agents | 10 | 2016 | 80 | 1.860 |
Why?
|
| Tissue Plasminogen Activator | 8 | 2016 | 126 | 1.850 |
Why?
|
| Cerebrovascular Circulation | 13 | 2012 | 228 | 1.520 |
Why?
|
| Clinical Trials as Topic | 15 | 2016 | 462 | 1.480 |
Why?
|
| Infarction, Middle Cerebral Artery | 7 | 2009 | 99 | 1.460 |
Why?
|
| Periodicals as Topic | 4 | 2017 | 178 | 1.300 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 11 | 2009 | 172 | 1.260 |
Why?
|
| Thrombectomy | 3 | 2019 | 263 | 1.110 |
Why?
|
| Endovascular Procedures | 4 | 2019 | 633 | 1.020 |
Why?
|
| Fibrinolytic Agents | 5 | 2010 | 183 | 1.000 |
Why?
|
| Editorial Policies | 2 | 2017 | 54 | 0.920 |
Why?
|
| Thrombolytic Therapy | 7 | 2016 | 205 | 0.910 |
Why?
|
| Reperfusion Injury | 4 | 2016 | 58 | 0.820 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2009 | 235 | 0.810 |
Why?
|
| Disease Models, Animal | 14 | 2013 | 2329 | 0.780 |
Why?
|
| Ischemic Attack, Transient | 4 | 2018 | 96 | 0.710 |
Why?
|
| Rats | 17 | 2013 | 2005 | 0.660 |
Why?
|
| Time Factors | 16 | 2019 | 3777 | 0.600 |
Why?
|
| Reperfusion | 5 | 2010 | 38 | 0.600 |
Why?
|
| Drug Design | 3 | 2010 | 139 | 0.570 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2009 | 2324 | 0.560 |
Why?
|
| Treatment Outcome | 13 | 2020 | 5834 | 0.530 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 196 | 0.520 |
Why?
|
| Animals | 31 | 2016 | 21492 | 0.500 |
Why?
|
| Anticoagulants | 5 | 2020 | 529 | 0.500 |
Why?
|
| Brain | 7 | 2007 | 1672 | 0.480 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2006 | 202 | 0.460 |
Why?
|
| Health Planning Guidelines | 2 | 2007 | 31 | 0.450 |
Why?
|
| Warfarin | 3 | 2020 | 125 | 0.440 |
Why?
|
| Humans | 43 | 2020 | 65830 | 0.430 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2008 | 626 | 0.430 |
Why?
|
| Ticlopidine | 2 | 2006 | 47 | 0.430 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2013 | 41 | 0.400 |
Why?
|
| Acute Disease | 8 | 2010 | 665 | 0.360 |
Why?
|
| Freezing | 1 | 2011 | 22 | 0.350 |
Why?
|
| Recovery of Function | 4 | 2019 | 293 | 0.340 |
Why?
|
| Embolism | 2 | 2008 | 41 | 0.330 |
Why?
|
| Thrombophilia | 1 | 2010 | 14 | 0.330 |
Why?
|
| Brain Injuries | 2 | 2013 | 141 | 0.320 |
Why?
|
| Aspirin | 2 | 2009 | 172 | 0.310 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 345 | 0.300 |
Why?
|
| Research | 2 | 2009 | 195 | 0.290 |
Why?
|
| Cerebral Infarction | 2 | 2007 | 88 | 0.290 |
Why?
|
| Intracranial Embolism | 1 | 2009 | 41 | 0.290 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2008 | 7 | 0.290 |
Why?
|
| Gadolinium | 1 | 2009 | 111 | 0.280 |
Why?
|
| Brain Infarction | 1 | 2008 | 21 | 0.280 |
Why?
|
| Hyperoxia | 1 | 2008 | 16 | 0.280 |
Why?
|
| Behavior, Animal | 2 | 2007 | 234 | 0.280 |
Why?
|
| Male | 22 | 2019 | 31403 | 0.280 |
Why?
|
| Biomedical Technology | 1 | 2007 | 6 | 0.250 |
Why?
|
| Contrast Media | 1 | 2009 | 435 | 0.250 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 45 | 0.240 |
Why?
|
| Rats, Wistar | 4 | 2013 | 184 | 0.240 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 884 | 0.240 |
Why?
|
| Middle Cerebral Artery | 1 | 2006 | 53 | 0.230 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2005 | 16 | 0.230 |
Why?
|
| Membrane Proteins | 1 | 2011 | 926 | 0.230 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 95 | 0.220 |
Why?
|
| Device Approval | 1 | 2005 | 13 | 0.220 |
Why?
|
| Telemedicine | 2 | 2009 | 379 | 0.210 |
Why?
|
| Diffusion | 5 | 2008 | 83 | 0.210 |
Why?
|
| Research Design | 2 | 2005 | 589 | 0.200 |
Why?
|
| Recombinant Proteins | 3 | 2016 | 710 | 0.200 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 276 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 214 | 0.190 |
Why?
|
| Patient Selection | 3 | 2016 | 484 | 0.190 |
Why?
|
| Stem Cell Transplantation | 1 | 2003 | 79 | 0.190 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 38 | 0.180 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2002 | 27 | 0.180 |
Why?
|
| Neurons | 2 | 2011 | 935 | 0.170 |
Why?
|
| Blood Pressure | 3 | 2010 | 537 | 0.170 |
Why?
|
| Disease Management | 1 | 2003 | 235 | 0.170 |
Why?
|
| Heparin | 1 | 2002 | 120 | 0.170 |
Why?
|
| Astrocytes | 1 | 2002 | 123 | 0.170 |
Why?
|
| Neuroimaging | 2 | 2013 | 170 | 0.170 |
Why?
|
| Injections, Intravenous | 3 | 2006 | 160 | 0.160 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 462 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 5681 | 0.160 |
Why?
|
| Risk Factors | 4 | 2019 | 5475 | 0.150 |
Why?
|
| China | 1 | 2019 | 181 | 0.140 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.140 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.140 |
Why?
|
| Disability Evaluation | 1 | 2019 | 216 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 1663 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2019 | 2115 | 0.140 |
Why?
|
| Regional Blood Flow | 2 | 2008 | 117 | 0.130 |
Why?
|
| Homes for the Aged | 1 | 2019 | 166 | 0.130 |
Why?
|
| Hemorrhage | 3 | 2019 | 287 | 0.130 |
Why?
|
| Protein C | 1 | 2016 | 26 | 0.120 |
Why?
|
| Secondary Prevention | 3 | 2018 | 165 | 0.120 |
Why?
|
| Aged | 6 | 2020 | 15145 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1117 | 0.120 |
Why?
|
| Neurology | 1 | 2016 | 44 | 0.120 |
Why?
|
| Nursing Homes | 2 | 2020 | 701 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2016 | 138 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 220 | 0.110 |
Why?
|
| Registries | 1 | 2019 | 935 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 1719 | 0.110 |
Why?
|
| Middle Aged | 4 | 2019 | 18498 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 711 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2009 | 809 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 2 | 2005 | 100 | 0.100 |
Why?
|
| Diagnostic Imaging | 2 | 2008 | 274 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6955 | 0.090 |
Why?
|
| Language | 1 | 2014 | 155 | 0.090 |
Why?
|
| United States | 5 | 2020 | 8186 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2013 | 224 | 0.090 |
Why?
|
| Tetrazolium Salts | 2 | 2008 | 14 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 603 | 0.090 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2011 | 21 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 240 | 0.080 |
Why?
|
| Factor V Deficiency | 1 | 2010 | 1 | 0.080 |
Why?
|
| Protein S Deficiency | 1 | 2010 | 1 | 0.080 |
Why?
|
| Protein C Deficiency | 1 | 2010 | 2 | 0.080 |
Why?
|
| Antithrombin III Deficiency | 1 | 2010 | 2 | 0.080 |
Why?
|
| Medicare | 3 | 2020 | 629 | 0.080 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 12 | 0.080 |
Why?
|
| Cell Death | 1 | 2011 | 289 | 0.080 |
Why?
|
| Female | 5 | 2019 | 34420 | 0.070 |
Why?
|
| Cortical Spreading Depression | 1 | 2009 | 9 | 0.070 |
Why?
|
| Hospital Units | 1 | 2009 | 9 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 319 | 0.070 |
Why?
|
| Health Care Sector | 1 | 2009 | 20 | 0.070 |
Why?
|
| Magnetic Field Therapy | 1 | 2008 | 3 | 0.070 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 13 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2020 | 371 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2006 | 141 | 0.070 |
Why?
|
| Species Specificity | 1 | 2009 | 344 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 159 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 296 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 193 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2010 | 502 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2007 | 715 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1146 | 0.060 |
Why?
|
| Peptides | 1 | 2011 | 593 | 0.060 |
Why?
|
| Injury Severity Score | 1 | 2007 | 117 | 0.060 |
Why?
|
| Equipment Design | 1 | 2008 | 374 | 0.060 |
Why?
|
| Virginia | 1 | 2007 | 27 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2194 | 0.060 |
Why?
|
| Radiography | 2 | 2006 | 559 | 0.060 |
Why?
|
| Benzenesulfonates | 1 | 2006 | 14 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 741 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2009 | 556 | 0.060 |
Why?
|
| Rats, Inbred WKY | 1 | 2005 | 11 | 0.060 |
Why?
|
| Brain Mapping | 1 | 2007 | 247 | 0.060 |
Why?
|
| Body Temperature | 1 | 2005 | 46 | 0.060 |
Why?
|
| Drug Industry | 1 | 2005 | 41 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2005 | 81 | 0.050 |
Why?
|
| Legislation, Drug | 1 | 2005 | 22 | 0.050 |
Why?
|
| Equipment Safety | 1 | 2005 | 29 | 0.050 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 26 | 0.050 |
Why?
|
| Drug Approval | 1 | 2005 | 28 | 0.050 |
Why?
|
| Models, Animal | 1 | 2005 | 242 | 0.050 |
Why?
|
| Risk | 1 | 2005 | 375 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 92 | 0.050 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 89 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 498 | 0.050 |
Why?
|
| Aspirin, Dipyridamole Drug Combination | 1 | 2003 | 3 | 0.050 |
Why?
|
| Dipyridamole | 1 | 2003 | 17 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2008 | 535 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 465 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2005 | 126 | 0.050 |
Why?
|
| Heart Rate | 1 | 2005 | 335 | 0.050 |
Why?
|
| Software | 1 | 2007 | 401 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2003 | 167 | 0.050 |
Why?
|
| Thrombosis | 1 | 2006 | 207 | 0.050 |
Why?
|
| Oxygen | 1 | 2005 | 323 | 0.050 |
Why?
|
| Recurrence | 1 | 2005 | 665 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2005 | 757 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2020 | 2651 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 932 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2003 | 142 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 375 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2003 | 208 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 254 | 0.040 |
Why?
|
| Adult | 2 | 2009 | 17575 | 0.040 |
Why?
|
| Disease Progression | 1 | 2005 | 1229 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 430 | 0.040 |
Why?
|
| Water | 1 | 2002 | 323 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 1569 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 2500 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2007 | 3339 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2019 | 40 | 0.040 |
Why?
|
| Algorithms | 1 | 2004 | 1060 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 71 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2018 | 74 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2019 | 289 | 0.030 |
Why?
|
| Skilled Nursing Facilities | 1 | 2018 | 80 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2019 | 204 | 0.030 |
Why?
|
| Urbanization | 1 | 2017 | 2 | 0.030 |
Why?
|
| Mice | 1 | 2011 | 11185 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 746 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2017 | 78 | 0.030 |
Why?
|
| Mechanical Thrombolysis | 1 | 2016 | 36 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2016 | 747 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 149 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 922 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2739 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 420 | 0.020 |
Why?
|
| Silicon | 1 | 2006 | 17 | 0.020 |
Why?
|
| Sutures | 1 | 2006 | 40 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 83 | 0.020 |
Why?
|
| Surface Properties | 1 | 2006 | 283 | 0.010 |
Why?
|